Clinical Research Details

Descriptive Information
Evaluation of the best sequence of treatments for metastatic breast cancer

Hazem Assi



Juliett Berro
Conditions and Keywords
breast cancer,metastatic,recurrent ,progressive
PFS,OS,chemotherapy regimens,endocrine therapy
Study Design
Safety and/or Efficacy Study
N/A: Not Applicable
N/A: Not Applicable
N/A: Not Applicable
Eligibility and IRB
Min: 18
In Progress

Breast cancer is the most common type of malignancy affecting females worldwide, in addition to being among the leading causes of mortality in this population of patients. The heterogeneity of this disease is related to the different characteristics inherent to every tumor, including histological features such as the grade, the hormone receptor and Her 2-neu status, among multiple others. These latter affect the choice of therapy in various stages of the disease. Moreover, with the recent development and approval of new agents for both the hormone receptor positive, it is important to explore the preferences of Lebanese oncologists guiding choices of the type; as well as the specific sequence of agents used, mainly in hormone receptor positive disease

Medical Charts of patients who were treated at the American University of Beirut Medical Center for metastatic breast cancer whether newly diagnosed, or recurring with metastatic disease, between the years 2016 and 2018 will be reviewed

Patients older than 18 years of age

-Patients with hormone receptor positive, HER 2 negative metastatic breast cancer

-Patients presenting with a new diagnosis of metastatic breast cancer (recurrence or de novo)

- Patients with non-metastatic breast cancer

- Patients with HER 2 positive metastatic breast cancer

- Patients diagnosed with metastatic breast cancer before January 2016